keyword
MENU ▼
Read by QxMD icon Read
search

Eovist

keyword
https://www.readbyqxmd.com/read/27633531/gadoxetate-disodium-gd-eob-dtpa-contrast-enhanced-magnetic-resonance-imaging-characteristics-of-hepatocellular-carcinoma-in-dogs
#1
Chase Constant, Silke Hecht, Linden E Craig, Cassie N Lux, Claire M Cannon, Gordon A Conklin
Hepatocellular carcinoma is the most common primary hepatic tumor in dogs and is amenable to surgical resection in many cases. Unfortunately, overlap of sonographic findings between benign and malignant hepatic lesions typically requires more invasive diagnostic tests to be performed (e.g., biopsy for histopathology). The availability of a noninvasive diagnostic test to identify hepatocellular carcinoma would be beneficial. The use of a liver-specific magnetic resonance imaging (MRI) contrast agent such as gadoxetate disodium (Gd-EOB-DTPA; Eovist® or Primovist®) has improved lesion detection in human patients...
November 2016: Veterinary Radiology & Ultrasound
https://www.readbyqxmd.com/read/27257451/transient-washout-of-hepatic-hemangiomas-potential-pitfall-mimicking-malignancy
#2
David J S Becker-Weidman, Thomas A Hope, Pooja H Doshi, Anuj Patel, Donald G Mitchell
Hemangiomas are the most common tumor of the liver and distinguishing them from malignancy is important. This is a report of 3 hemangiomas in 2 patients that exhibit transient washout of gadoxetate disodium (Eovist), relative to blood pool and liver parenchyma, a characteristic that is used to diagnose hepatocellular carcinoma in at-risk patients. It is important to recognize that high-flow hemangiomas can exhibit transient washout when using a small volume of injected contrast agent. This finding is unlikely to be present on CT examinations because of the larger volume of contrast administered...
June 2016: Radiology case reports
https://www.readbyqxmd.com/read/27017170/colorectal-liver-metastases-disappearing-lesions-in-the-era-of-eovist-hepatobiliary-magnetic-resonance-imaging
#3
Joseph W Owen, Kathryn J Fowler, Maria B Doyle, Nael E Saad, David C Linehan, William C Chapman
BACKGROUND: Hepatobiliary contrast enhanced MRI is known to be the most sensitive imaging modality for detection of colorectal hepatic metastasis. To date no study has investigated the rate of disappearing lesions with gadoxetic acid MR (Eovist/Primovist), or characterized the pathologic response of lesions which disappear on gadoxetic acid MR. METHODS: Retrospective review of hepatic resections for colorectal metastases between 01/2008 and 01/2014 was performed to evaluated the rate of disappearance of lesions on gadoxetic acid MR and the rate of complete pathologic response in the lesions that disappear...
March 2016: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
https://www.readbyqxmd.com/read/26863577/macrocyclic-and-other-non-group-1-gadolinium-contrast-agents-deposit-low-levels-of-gadolinium-in-brain-and-bone-tissue-preliminary-results-from-9-patients-with-normal-renal-function
#4
Nozomu Murata, Luis F Gonzalez-Cuyar, Kiyoko Murata, Corinne Fligner, Russell Dills, Daniel Hippe, Kenneth R Maravilla
OBJECTIVE: The purpose of this study was to determine whether gadolinium (Gd) is deposited in brain and bone tissues in patients receiving only non-Group 1 agents, either macrocyclic or linear protein interacting Gd-based contrast agents, with normal renal function. Group 1 agents are linear agents most associated with nephrogenic systemic fibrosis that the US Federal Drug Administration has defined as contraindicated in patients at risk for this disease. MATERIALS AND METHODS: This study was institutional review board approved and Health Insurance Portability and Accountability Act compliant for retrospective review of records and also had signed autopsy consent authorizing use of decedent's tissue in research studies...
July 2016: Investigative Radiology
https://www.readbyqxmd.com/read/26609347/pseudolymphoma-reactive-lymphoid-hyperplasia-of-the-liver-a-clinical-challenge
#5
Yong Kyong Kwon, Reena C Jha, Kambiz Etesami, Thomas M Fishbein, Metin Ozdemirli, Chirag S Desai
Reactive lymphoid hyperplasia (RLH), also known as pseudolymphoma or nodular lymphoid lesion of the liver is an extremely rare condition, and only 51 hepatic RLH cases have been described in the literature since the first case was described in 1981. The majority of these cases were asymptomatic and incidentally found through radiological imaging. The precise etiology of hepatic RLH is still unknown, but relative high prevalence of autoimmune disorder in these cases suggests an immune-based liver disorder. Imaging features of hepatic RLH often suggest malignant lesions such as hepatocellular carcinoma and cholangiocarcinoma...
November 18, 2015: World Journal of Hepatology
https://www.readbyqxmd.com/read/26341966/liver-and-bone-metastases-from-breast-cancer-eovist-magnetic-resonance-and-diffusion-weighted-imaging-18f-fdg-positron-emission-computed-tomography
#6
Fabrizio Chegai, Serena Monti, Antonio Orlacchio, Lorenzo Mannelli
No abstract text is available yet for this article.
February 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/26129563/th-cd-207-05-combined-effects-of-gadolinium-contrast-and-inversion-recovery-pulse-on-quantitative-adc-measurements-in-the-liver
#7
A Panda, J James, D Chavez, A Silva
PURPOSE: Performing diffusion weighted imaging (DWI) immediately after Gadolinium (Gd) contrast administration is considered to have insignificant impact on apparent diffusion coefficient (ADC) measurements in the liver. However, our observation contradicts those findings. The goal of this study was to evaluate the impact of Gd and inversion recovery (IR) pulse on ADC measurements in the liver. METHODS: DWI data was acquired on a 1.5T MRI scanner using 8-channel body coil from four patients pre-, 10-min post-, and 20-min post contrast with a TI of 0 (no fat suppression) and 120 ms, respectively...
June 2015: Medical Physics
https://www.readbyqxmd.com/read/26048848/safety-of-gadoxetate-disodium-results-from-six-clinical-phase-iv-studies-in-8194-patients
#8
Jan Endrikat, So Yeon Kim, Toshiaki Sakaguchi, Susan Dohanish, Josy Breuer
BACKGROUND: Safety data on routine clinical use of gadoxetate disodium for liver magnetic resonance imaging (MRI) is not reported yet. PURPOSE: To assess the safety profile of gadoxetate disodium for liver MRI in the routine clinical setting. MATERIAL AND METHODS: Six multicenter studies were performed in Europe, USA, Australia, and Asia to evaluate the safety and efficacy of gadoxetate disodium (Primovist®/Eovist®) enhanced liver MRI. Patients received a single intravenous bolus injection of the standard approved dose of 0...
June 4, 2015: Acta Radiologica
https://www.readbyqxmd.com/read/25478742/improved-detection-of-hypervascular-liver-lesions-with-caipirinha-dixon-twist-volume-interpolated-breath-hold-examination
#9
Philipp M Kazmierczak, Daniel Theisen, Kolja M Thierfelder, Wieland H Sommer, Maximilian F Reiser, Mike Notohamiprodjo, Konstantin Nikolaou
OBJECTIVES: The aim of this study was to assess the diagnostic performance of a dynamic, multiphasic contrast-enhanced volume-interpolated sequence with advanced parallel imaging techniques, Dixon fat saturation, and view sharing with 5 hepatic arterial subphases for the detection of focal liver lesions. MATERIALS AND METHODS: Twenty-four consecutive patients (13 females, 11 males; mean [SD] age, 58 [15] years) with focal liver lesions were included in this prospective study...
March 2015: Investigative Radiology
https://www.readbyqxmd.com/read/25319036/mri-with-gadoxetate-disodium-for-colorectal-liver-metastasis-is-it-the-new-imaging-modality-of-choice
#10
Shirali Patel, Susannah Cheek, Houssam Osman, D Rohan Jeyarajah
BACKGROUND: Accurate detection of colorectal liver metastasis is paramount in the role of management. This study aims to compare magnetic resonance imaging (MRI) with gadoxetate disodium (a hepatocyte-specific agent-Eovist®) to triple-phase enhanced computed tomography in detecting colorectal liver metastases. METHODS: A retrospective chart analysis of 30 patients from 2011 to 2013 with colorectal liver metastases was performed. Patients with more than 6 weeks or two cycles of chemotherapy between the two imaging modalities were excluded...
December 2014: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/24945024/effects-of-gadoxetate-disodium-eovist-%C3%A2-contrast-on-magnetic-resonance-imaging-characteristics-of-the-liver-in-clinically-healthy-dogs
#11
Alyce L Marks, Silke Hecht, Jennifer E Stokes, Gordon A Conklin, Katherine H Deanna
Gadoxetate disodium (Gd-EOB-DTPA; gadolinium-ethoxybenzyl-diethylene triamine penta-acetic acid) is a newly developed paramagnetic contrast agent reported to have a high specificity for the hepatobiliary system in humans. The purpose of this prospective study was to describe effects of Gd-EOB-DTPA contrast administration on MRI characteristics of the liver in eight clinically healthy dogs. Precontrast dorsal and transverse T1-weighted spin echo, T2-weighted fast spin echo, and transverse T1-weighted 3D gradient echo (VIBE; volume-interpolated body examination) pulse sequences were acquired for each dog...
May 2014: Veterinary Radiology & Ultrasound
https://www.readbyqxmd.com/read/24056116/characterization-of-the-intestinal-and-hepatic-uptake-efflux-transport-of-the-magnetic-resonance-imaging-contrast-agent-gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic-acid
#12
Jia Jia, Dorothee Puls, Stefan Oswald, Gabriele Jedlitschky, Jens P Kühn, Werner Weitschies, Norbert Hosten, Werner Siegmund, Markus Keiser
OBJECTIVES: The objectives of the study were to measure the pharmacokinetics and liver enhancement of gadoxetate (gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid [Gd-EOB-DTPA], Eovist, Primovist) after oral and intravenous administration in wild-type and (multidrug resistance-associated protein 2) Mrp2-deficient rats and to evaluate the in vitro transport of the contrast agent via intestinal and hepatic transporter proteins. MATERIALS AND METHODS: Gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid-enhanced magnetic resonance imaging and pharmacokinetics of Gd-EOB-DTPA after intravenous and oral administration were evaluated in wild-type and Mrp2-deficient rats using T1-weighted magnetic resonance imaging and a validated liquid chromatography-mass spectrometry method, respectively...
February 2014: Investigative Radiology
https://www.readbyqxmd.com/read/23653860/gd-eob-dtpa-enhanced-mri-for-detection-of-liver-metastases-from-colorectal-cancer-a-surgeon-s-perspective
#13
Kelly J Lafaro, Panayota Roumanis, Aram N Demirjian, Chandana Lall, David K Imagawa
Colorectal cancer affects over one million people worldwide annually, with the liver being the most common site of metastatic spread. Adequate resection of hepatic metastases is the only chance for a cure in a subset of patients, and five-year survival increases to 35% with complete resection. Traditionally, computed tomographic imaging (CT) was utilized for staging and to evaluate metastases in the liver. Recently, the introduction of hepatobiliary contrast-enhanced magnetic resonance imaging (MRI) agents including gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Eovist in the United States, Primovist in Europe, or Gd-EOB-DTPA) has proved to be a sensitive method for detection of hepatic metastases...
2013: International Journal of Hepatology
https://www.readbyqxmd.com/read/23159401/imaging-features-of-intrahepatic-cholangiocarcinoma-in-gd-eob-dtpa-enhanced-mri
#14
Anne R J Péporté, Wieland H Sommer, Konstantin Nikolaou, Maximilian F Reiser, Christoph J Zech
OBJECTIVE: The aim of this study is to describe the imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI and to determine whether it results in improved tumour conspicuity of cholangiocarcinoma. MATERIALS AND METHODS: Fifty-four patients with histologically proven intrahepatic cholangiocarcinoma underwent MRI of the liver using a 1.5T MR-scanner with Gadoxetic acid disodium (Gd-EOB-DTPA; Eovist/Primovist, Bayer Healthcare, Berlin, Germany)...
March 2013: European Journal of Radiology
https://www.readbyqxmd.com/read/22504332/primovist-eovist-what-to-expect
#15
REVIEW
Bernard E Van Beers, Catherine M Pastor, Hero K Hussain
Gadolinium ethoxybenzyl dimeglumine (Gd-EOB-DTPA, Primovist in Europe and Eovist in the USA) is a liver-specific magnetic resonance imaging contrast agent that has up to 50% hepatobiliary excretion in the normal liver. After intravenous injection, Gd-EOB-DTPA distributes into the vascular and extravascular spaces during the arterial, portal venous and late dynamic phases, and progressively into the hepatocytes and bile ducts during the hepatobiliary phase. The hepatocyte uptake of Gd-EOB-DTPA mainly occurs via the organic anion transporter polypeptides OATP1B1 and B3 located at the sinusoidal membrane and biliary excretion via the multidrug resistance-associated proteins MRP2 at the canalicular membrane...
August 2012: Journal of Hepatology
https://www.readbyqxmd.com/read/21623212/pharmacokinetics-and-imaging-properties-of-gd-eob-dtpa-in-patients-with-hepatic-and-renal-impairment
#16
COMPARATIVE STUDY
Simone Gschwend, Wolfgang Ebert, Marcus Schultze-Mosgau, Josy Breuer
OBJECTIVES: : The purpose of this study was to determine the pharmacokinetics (PKs), imaging properties, and safety of the liver-specific magnetic resonance (MR) imaging contrast agent gadoxetic acid disodium (Gd-EOB-DTPA) in subjects with various levels of hepatic impairment, renal impairment, or coexisting hepatic and renal impairment. MATERIALS AND METHODS: : In this single-center, open-label, parallel-group study, patients with varying degrees of renal and/or hepatic impairment were compared with healthy subjects matched for age, gender, and weight (control group)...
September 2011: Investigative Radiology
https://www.readbyqxmd.com/read/21285889/evaluation-of-the-effect-of-two-gadolinium-containing-contrast-enhancing-agents-gadobutrol-and-gadoxetate-disodium-on-colorimetric-calcium-determinations-in-serum-and-plasma
#17
Andrea Löwe, Josy Breuer, Petra Palkowitsch
OBJECTIVE: To determine the extent to which the gadolinium-containing contrast agents, gadobutrol (Gadovist) and gadoxetate disodium (Primovist/Eovist), interfere with the colorimetric measurement of calcium concentrations in serum and plasma. MATERIALS AND METHODS: Gadobutrol and gadoxetate disodium were added in various concentrations to serum and plasma from healthy volunteers; the calcium concentration in these samples was then measured by standard colorimetry methods and atomic absorption...
June 2011: Investigative Radiology
https://www.readbyqxmd.com/read/21161026/multiple-progressive-focal-nodular-hyperplasia-lesions-of-liver-in-a-patient-with-hemosiderosis
#18
Arda Kayhan, Nanda Venu, Hatice Lakadamyalı, Donald Jensen, Aytekin Oto
Focal nodular hyperplasia (FNH) is the second most common benign lesion of the liver. It is a solitary lesion and usually does not enlarge. We present the magnetic resonance imaging findings of multiple progressive FNH lesions in a patient with hemosiderosis using Gadolinium-EOB-DTPA (Eovist) as a hepatobiliary contrast agent. The possible mechanisms underlying the occurrence and progression of FNH lesions and the potential value of Eovist in characterizing the lesions were discussed.
October 28, 2010: World Journal of Radiology
https://www.readbyqxmd.com/read/20677260/focal-nodular-hyperplasia-central-scar-enhancement-pattern-using-gadoxetate-disodium
#19
Adib R Karam, Sridhar Shankar, Padmaja Surapaneni, Young H Kim, Sarwat Hussain
PURPOSE: To illustrate the unusual enhancement pattern of the focal nodular hyperplasia central scar using Gadoxetate Disodium. MATERIALS AND METHODS: Over a 10-month period, six patients, with a total of seven focal nodular hyperplasia lesions with typical central scar, had MRI of the liver using Gadoxetate Disodium (Eovist, Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ). Four of the six patients had a prior Gadobenate Dimeglumine (Multihance, Bracco Diagnostics Inc...
August 2010: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/15230630/gadoxate-disodium-gadolinium-eob-dtpa-gadoxetic-acid-gd-eob-dtpa
#20
REVIEW
(no author information available yet)
Gadoxate disodium [gadolinium EOB DTPA, Gd-EOB-DTPA, gadoxetic acid, Eovist injection, Primovist] is a hydrophilic paramagnetic contrast agent being developed by Schering AG for hepatobiliary magnetic resonance imaging. In April 2004, gadoxate disodium (Primovist) was approved in Sweden, the reference member state for the EU registration. Following the Swedish approval, Schering will initiate a mutual recognition procedure for the EU with approvals expected in most countries during 2004. Gadoxate disodium is in phase III clinical trials in the US and has completed phase III studies in Japan...
2004: Drugs in R&D
keyword
keyword
27809
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"